RATIFY: midostaurin added to chemotherapy for acute myeloid leukaemia with a FLT3 mutation
Adding the FLT3 inhibitor midostaurin to standard induction and consolidation chemotherapy, then as maintenance, lengthened survival in adults under 60 with FLT3-mutated acute myeloid leukaemia, the first targeted drug to do so.
Overview
Phase 3 placebo-controlled trial of 717 patients aged 18 to 59 with newly diagnosed FLT3-mutated AML (ITD or TKD) randomised to midostaurin or placebo with daunorubicin-cytarabine induction, high-dose cytarabine consolidation and a year of maintenance.
Median overall survival was 74.7 months with midostaurin against 25.6 months with placebo (hazard ratio 0.78), with benefit across FLT3 subtypes and in patients who went on to transplant.
- Median overall survival 74.7 vs 25.6 months; hazard ratio for death 0.78.
- Four-year overall survival 51.4 percent vs 44.3 percent.
FLT3 testing at diagnosis and a FLT3 inhibitor during chemotherapy became standard. Quizartinib (QuANTUM-First) is an alternative for FLT3-ITD, and the approach extended FLT3 inhibitors into maintenance and relapse.
- Patients over 60 were excluded.
- The contribution of maintenance midostaurin could not be isolated.
Similar pages
not linked directly; found by shared links- TermFLT3-ITD allelic ratio
Shares RATIFY (CALGB 10603), FLT3-mutated acute myeloid leukaemia.
- PairingFLT3 inhibitor + intensive chemotherapy
Shares RATIFY (CALGB 10603), Midostaurin, FLT3-mutated acute myeloid leukaemia.
- Key paperADMIRAL: gilteritinib pills versus chemotherapy for relapsed FLT3-mutated acute myeloid leukaemia
Shares Midostaurin, FLT3-mutated acute myeloid leukaemia, New England Journal of Medicine.
- Term7+3 induction chemotherapy
- Key paperQuANTUM-First: quizartinib added to intensive chemotherapy and continued as maintenance in newly diagnosed FLT3-ITD AML
- TermELN 2022 risk classification
Shares RATIFY (CALGB 10603), FLT3-mutated acute myeloid leukaemia.
- TreatmentCytarabine + anthracycline ('7+3')
Shares RATIFY (CALGB 10603), FLT3-mutated acute myeloid leukaemia.
- TargetFLT3
Shares RATIFY (CALGB 10603), Midostaurin, FLT3-mutated acute myeloid leukaemia.